
About Trident Lifeline
Trident Lifeline is a publicly listed company based in Surat (India) founded in 2014. Manufacturer of liquid orals, topical preparations, capsule, and other drugs. The company has 74 employees. Trident Lifeline has completed 1 acquisition, including Tll Herbal. Its Indian entity Trident Lifeline Limited reported revenue of βΉ138 Cr. Trident Lifeline offers products and services including Pharmaceuticals and Nutraceuticals. Its focus areas include Traditional Pharmaceuticals and Diversified.
Company details
Trident Lifeline was established in 2014 in Surat, India, within the pharmaceutical sector. Operations focus on the production of liquid orals, topical preparations, capsules, and additional drug formulations. Manufacturing activities are centered in India, supporting domestic pharmaceutical needs. Leadership is provided by Managing Director Hardik Desai, with the company maintaining a domain at tridentlifeline.com for operational purposes.
- Headquarters Surat, India
- Employees 74
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website tridentlifeline.com
- Social LinkedIn X Facebook Instagram
- Legal Name Trident Lifeline Ltd.
- Market Cap₹491 Cr
TLL · BSE
- Share Price₹406.05
-0.96% today
- Revenue₹129 Cr
FY 2025-26 · +48.4% YoY
- EBITDA₹28.11 Cr
Margin 21.8%
- Net Profit₹19.03 Cr
FY 2025-26 · +62.2% YoY
- P/E (TTM)21.1x
P/B 4.2x
- ROE23.4%
ROCE 22.3%
- Debt / Equity0.77
Interest cover 24.1x
- Employee Count74
- Investments & Acquisitions
Associated legal entities of Trident Lifeline
Trident Lifeline operates through Trident Lifeline Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Trident Lifeline Limited Listed CIN L51909GJ2014PLC078227 | Active | 09 Jan 2014 | Surat, Gujarat | ₹138 Cr | 27 | 10 | View details |
Products & Services of Trident Lifeline
Trident Lifeline offers a comprehensive portfolio of products and services, including Pharmaceuticals and Nutraceuticals.
High-quality medicines are manufactured and marketed by Trident Lifeline, including tablets, capsules, and oral liquids, to address various healthcare requirements.
Nutritional supplements are formulated by Trident Lifeline to promote wellness, encompassing tablets, capsules, and sachets for supporting a healthy lifestyle.
Board of directors of Trident Lifeline Limited (Trident Lifeline)
Trident Lifeline Limited is the primary company behind Trident Lifeline. The board of Trident Lifeline Limited currently have 8 directors; the longest-serving is Hardik Jigishkumar Desai, appointed in 2022. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Hardik Jigishkumar Desai DIN 01358227 | Director | 27 Jun 2022 | 4 yrs 4 mo | Trident Lifeline Limited |
| Shravan H Patel DIN 08629141 | Managing Director | 04 Jul 2022 | 4 yrs 4 mo | Trident Lifeline Limited |
| Mishal Shailesh Patel DIN 10250091 | Director | 22 Jul 2023 | 3 yrs 4 mo | Trident Lifeline Limited |
| Falguni Bhavesh Jariwala DIN 10584711 | Director | 27 Apr 2024 | 2 yrs 6 mo | Trident Lifeline Limited |
| Rupaben Chetan Jariwala DIN 08543127 | Whole-time director | 16 May 2024 | 2 yrs 6 mo | Trident Lifeline Limited |
| Ashish Anandsingh Bafna DIN 01796556 | Director | 01 Sep 2025 | 1 yr 2 mo | Trident Lifeline Limited |
| Smita Kiran Davda DIN 11125469 | Director | 13 Jun 2026 | 5 mo | Trident Lifeline Limited |
| Sachin Bhandari DIN 11768182 | Director | 13 Jun 2026 | 5 mo | Trident Lifeline Limited |
People of Trident Lifeline
2 people are tracked at Trident Lifeline (2 in leadership); the tracked headcount is 74.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership | |
| Chief Executive Officer | Leadership |
Complete people profiles for Trident Lifeline
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Trident Lifeline
Trident Lifeline is a publicly listed company on the BSE with ticker symbol TLL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Oct 2022
- Listed onBSE: 543616
- Listed entityTrident Lifeline Ltd.
- Exchange sectorHealth technology
- ISININE0MKA01014
- Share price₹409.00 (+8.2% on the day) · 2026-10-14
- Market capitalisation₹451 Cr
- Price to earnings22.8
- EPS (diluted, trailing year)₹17.90
- Volume (last session)20,400
Financials of Trident Lifeline
Exchange-reported figures of Trident Lifeline Limited, the listed company behind Trident Lifeline (BSE: TLL).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 129 | 86.96 | 44.63 | 31.69 | 21.77 |
| Revenue growth | +48.4% | +94.9% | +40.8% | +45.6% | - |
| EBITDA | 28.11 | 15.00 | 8.23 | 6.26 | 2.71 |
| EBITDA margin | +21.8% | +17.3% | +18.4% | +19.8% | +12.5% |
| Profit before tax | 27.19 | 13.60 | 8.69 | 6.58 | 2.98 |
| Net profit | 19.03 | 11.73 | 6.33 | 6.02 | 3.94 |
| Net profit margin | +14.8% | +13.5% | +14.2% | +19.0% | +18.1% |
| EPS (βΉ) | 16.32 | 10.22 | 5.52 | 5.23 | 4.93 |
| Balance sheet | |||||
| Total assets | 181 | 124 | 72.43 | 54.87 | 7.30 |
| Net worth | 100 | 64.46 | 52.90 | 45.64 | 4.78 |
| Total debt | 72.99 | 54.03 | 18.41 | 7.69 | 2.46 |
| Cash & bank | 4.22 | 2.46 | 6.65 | 13.78 | 0.16 |
| Net working capital | 84.56 | 58.58 | 37.32 | 41.51 | 4.13 |
| Cash flow | |||||
| Cash from operations | 4.69 | (3.98) | 2.23 | (19.00) | (0.21) |
| Cash from investing | (36.61) | (13.71) | (20.36) | (9.69) | (0.45) |
| Cash from financing | 33.68 | 13.50 | 11.01 | 42.28 | 0.80 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.08 | 33.72 | 49.95 | 25.71 | 31.34 | 23.61 | 34.01 | 11.83 |
| Revenue growth (YoY) | +50.2% | +42.8% | +46.9% | +117.3% | +102.9% | +79.5% | - | - |
| Other income | 0.97 | 0.57 | 1.62 | 4.63 | 1.67 | 1.35 | 1.87 | 0.56 |
| EBITDA | 11.32 | 8.52 | 10.98 | 5.09 | 6.86 | 5.17 | 8.53 | 4.08 |
| EBITDA margin | +24.0% | +25.3% | +22.0% | +19.8% | +21.9% | +21.9% | +25.1% | +34.5% |
| Depreciation | 1.56 | 1.62 | 1.23 | 2.46 | 0.91 | 1.46 | 2.74 | 0.61 |
| Interest | 1.93 | 0.86 | 0.77 | 1.24 | 0.99 | 1.13 | 1.55 | 0.55 |
| Profit before tax | 8.80 | 6.61 | 10.60 | 6.02 | 6.63 | 3.93 | 6.11 | 3.48 |
| Tax | 2.21 | 1.54 | 3.82 | 1.37 | 1.54 | 1.15 | (0.02) | 0.92 |
| Net profit | 6.59 | 5.07 | 6.78 | 4.65 | 5.09 | 2.78 | 6.13 | 2.56 |
| EPS (βΉ) | 5.69 | 4.27 | 5.76 | 3.72 | 4.27 | 2.66 | 6.15 | 2.42 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 102 | 67.80 | 44.65 | 31.69 | 21.77 | 9.62 | 4.93 |
| Revenue growth | +50.3% | +51.9% | +40.9% | +45.6% | +126.3% | +95.1% | - |
| EBITDA | 24.33 | 17.66 | 8.87 | 6.26 | 2.71 | 1.26 | (0.28) |
| EBITDA margin | +23.9% | +26.1% | +19.9% | +19.8% | +12.5% | +13.1% | -5.7% |
| Profit before tax | 24.98 | 17.89 | 9.79 | 6.57 | 2.98 | 0.87 | (1.09) |
| Net profit | 18.09 | 13.04 | 7.03 | 6.01 | 3.94 | 0.65 | (0.82) |
| Net profit margin | +17.8% | +19.2% | +15.7% | +19.0% | +18.1% | +6.8% | -16.6% |
| EPS (βΉ) | 15.50 | 11.35 | 6.13 | 5.23 | 4.93 | 1.26 | (2.57) |
| Balance sheet | |||||||
| Total assets | 124 | 80.69 | 58.94 | 49.08 | 7.30 | 4.11 | 3.52 |
| Net worth | 99.09 | 65.73 | 52.68 | 45.63 | 4.78 | (0.47) | (3.00) |
| Total debt | 24.60 | 14.89 | 6.20 | 3.38 | 2.46 | 4.53 | 6.46 |
| Cash & bank | 4.07 | 2.11 | 6.01 | 13.77 | 0.13 | 0.09 | 0.12 |
| Net working capital | 75.54 | 52.49 | 38.69 | 40.44 | 4.11 | 0.40 | (0.05) |
| Cash flow | |||||||
| Cash from operations | 7.93 | 1.97 | 0.90 | (16.60) | (0.19) | 1.48 | (0.59) |
| Cash from investing | (20.07) | (7.88) | (11.01) | (5.56) | (0.50) | (0.56) | (0.08) |
| Cash from financing | 14.10 | 2.01 | 2.35 | 35.80 | 0.80 | (0.96) | 0.76 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.73 | 26.84 | 31.97 | 23.67 | 46.26 | 18.82 | 20.85 | 16.51 |
| Revenue growth (YoY) | -29.3% | +42.6% | +53.3% | +43.4% | +195.4% | +27.7% | - | - |
| Other income | 0.93 | 0.53 | 1.64 | 0.89 | 1.64 | 0.54 | 1.61 | 0.54 |
| Total expenses | 22.98 | 19.62 | 25.23 | 17.39 | 34.95 | 13.89 | 15.27 | 12.37 |
| EBITDA | 9.75 | 7.22 | 6.74 | 6.28 | 11.31 | 4.93 | 5.58 | 4.14 |
| EBITDA margin | +29.8% | +26.9% | +21.1% | +26.5% | +24.4% | +26.2% | +26.8% | +25.1% |
| Depreciation | 0.57 | 0.70 | 0.04 | 0.71 | 1.11 | 0.51 | 0.71 | 0.38 |
| Interest | 1.32 | 0.49 | 0.38 | 0.54 | 0.74 | 0.33 | 0.46 | 0.35 |
| Profit before tax | 8.79 | 6.56 | 7.96 | 5.92 | 11.10 | 4.63 | 6.02 | 3.95 |
| Tax | 2.21 | 1.54 | 2.29 | 1.91 | 2.69 | 1.15 | 1.66 | 0.92 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.08 | 33.72 | 49.95 | 25.71 | 31.34 | 23.61 | 34.01 | 11.83 |
| Revenue growth (YoY) | +50.2% | +42.8% | +46.9% | +117.3% | +102.9% | +79.5% | - | - |
| Other income | 0.97 | 0.57 | 1.62 | 4.63 | 1.67 | 1.35 | 1.87 | 0.56 |
| EBITDA | 11.32 | 8.52 | 10.98 | 5.09 | 6.86 | 5.17 | 8.53 | 4.08 |
| EBITDA margin | +24.0% | +25.3% | +22.0% | +19.8% | +21.9% | +21.9% | +25.1% | +34.5% |
| Depreciation | 1.56 | 1.62 | 1.23 | 2.46 | 0.91 | 1.46 | 2.74 | 0.61 |
| Interest | 1.93 | 0.86 | 0.77 | 1.24 | 0.99 | 1.13 | 1.55 | 0.55 |
| Profit before tax | 8.80 | 6.61 | 10.60 | 6.02 | 6.63 | 3.93 | 6.11 | 3.48 |
| Tax | 2.21 | 1.54 | 3.82 | 1.37 | 1.54 | 1.15 | (0.02) | 0.92 |
| Net profit | 6.59 | 5.07 | 6.78 | 4.65 | 5.09 | 2.78 | 6.13 | 2.56 |
| EPS (βΉ) | 5.69 | 4.27 | 5.76 | 3.72 | 4.27 | 2.66 | 6.15 | 2.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Revenue | 129 | 86.96 | 44.63 | 31.69 | 21.77 |
| Revenue growth | +48.4% | +94.9% | +40.8% | +45.6% | - |
| Other income | 9.27 | 8.23 | 2.08 | 1.16 | 0.60 |
| Total expenses | 101 | 71.96 | 36.40 | 25.43 | 19.06 |
| Employee cost | 0.00 | 10.89 | 2.29 | 1.39 | 1.10 |
| EBITDA | 28.11 | 15.00 | 8.23 | 6.26 | 2.71 |
| EBITDA margin | +21.8% | +17.3% | +18.4% | +19.8% | +12.5% |
| Depreciation | 6.07 | 5.49 | 0.97 | 0.36 | 0.20 |
| Interest | 4.12 | 4.14 | 0.65 | 0.48 | 0.13 |
| Profit before tax | 27.19 | 13.60 | 8.69 | 6.58 | 2.98 |
| Tax | 7.88 | 3.12 | 2.75 | 0.56 | (0.96) |
| Net profit | 19.03 | 11.73 | 6.33 | 6.02 | 3.94 |
| Net profit margin | +14.8% | +13.5% | +14.2% | +19.0% | +18.1% |
| EPS (βΉ) | 16.32 | 10.22 | 5.52 | 5.23 | 4.93 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 11.93 | 11.50 | 11.50 | 11.50 | 8.00 |
| Reserves & surplus | 84.74 | 52.96 | 40.41 | 34.14 | (3.22) |
| Shareholders' funds (net worth) | 100 | 64.46 | 52.90 | 45.64 | 4.78 |
| Minority interest | 7.49 | 5.19 | 1.05 | 1.47 | 0.00 |
| Secured loans | 56.65 | 41.15 | 14.42 | 6.20 | 0.60 |
| Unsecured loans | 16.34 | 12.88 | 3.99 | 1.49 | 1.86 |
| Total debt | 72.99 | 54.03 | 18.41 | 7.69 | 2.46 |
| Total liabilities | 181 | 124 | 72.43 | 54.87 | 7.30 |
| Assets | |||||
| Gross block | 78.30 | 57.40 | 23.03 | 4.33 | 2.23 |
| Net block | 60.70 | 43.87 | 20.89 | 3.16 | 1.43 |
| Capital work in progress | 17.54 | 1.60 | 4.03 | 4.83 | 0.00 |
| Investments | 8.27 | 10.72 | 3.77 | 3.34 | 0.00 |
| Inventories | 36.44 | 28.24 | 12.58 | 7.17 | 3.71 |
| Sundry debtors | 73.65 | 27.68 | 13.44 | 12.09 | 4.97 |
| Cash & bank balances | 4.22 | 2.46 | 6.65 | 13.78 | 0.16 |
| Loans & advances | 25.18 | 31.99 | 19.29 | 16.17 | 1.83 |
| Total current assets | 139 | 90.37 | 51.96 | 49.21 | 10.67 |
| Total current liabilities | 54.93 | 31.79 | 14.64 | 7.70 | 6.54 |
| Net working capital | 84.56 | 58.58 | 37.32 | 41.51 | 4.13 |
| Total assets | 181 | 124 | 72.43 | 54.87 | 7.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Opening cash | 2.46 | 6.65 | 13.78 | 0.18 | 0.01 |
| Net cash from operating activities | 4.69 | (3.98) | 2.23 | (19.00) | (0.21) |
| Net cash from investing activities | (36.61) | (13.71) | (20.36) | (9.69) | (0.45) |
| Net cash from financing activities | 33.68 | 13.50 | 11.01 | 42.28 | 0.80 |
| Net change in cash | 1.76 | (4.19) | (7.13) | 13.60 | 0.14 |
| Closing cash | 4.22 | 2.46 | 6.65 | 13.78 | 0.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +48.4% | +94.9% | +40.8% | +45.6% | - |
| EBITDA growth | +87.4% | +82.3% | +31.5% | +131.0% | - |
| PBT growth | +100.1% | +56.5% | +32.1% | +120.8% | +9997.0% |
| Net income growth | +62.2% | +85.3% | +5.2% | +52.8% | - |
| Revenue CAGR (3Y) | +59.7% | +58.7% | - | - | - |
| EBITDA CAGR (3Y) | +65.1% | +76.9% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | +15.0% | +12.1% | +13.3% | +19.0% | +18.1% |
| Return on capital employed | +22.3% | +18.7% | +15.0% | +22.1% | +29.7% |
| Return on net worth | +23.4% | +17.9% | +12.1% | +22.4% | +49.4% |
| Debt / equity | 0.77 | 0.62 | 0.26 | 0.20 | 0.51 |
| Long-term debt / equity | 0.43 | 0.38 | 0.17 | 0.10 | 0.30 |
| Interest cover | 24.09 | 43.53 | 8.95 | 8.14 | 5.18 |
| Efficiency & per share | |||||
| Fixed asset turnover | 1.90 | 2.16 | 3.26 | 9.66 | 9.76 |
| Inventory turnover | 3.99 | 4.26 | 4.52 | 5.83 | 5.87 |
| Debtors turnover | 2.55 | 4.23 | 3.50 | 3.72 | 4.38 |
| EPS (βΉ) | 15.96 | 10.22 | 5.52 | 5.23 | 4.93 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 81.02 | 56.05 | 45.14 | 39.69 | 5.97 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.73 | 26.84 | 31.97 | 23.67 | 46.26 | 18.82 | 20.85 | 16.51 |
| Revenue growth (YoY) | -29.3% | +42.6% | +53.3% | +43.4% | +195.4% | +27.7% | - | - |
| Other income | 0.93 | 0.53 | 1.64 | 0.89 | 1.64 | 0.54 | 1.61 | 0.54 |
| Total expenses | 22.98 | 19.62 | 25.23 | 17.39 | 34.95 | 13.89 | 15.27 | 12.37 |
| EBITDA | 9.75 | 7.22 | 6.74 | 6.28 | 11.31 | 4.93 | 5.58 | 4.14 |
| EBITDA margin | +29.8% | +26.9% | +21.1% | +26.5% | +24.4% | +26.2% | +26.8% | +25.1% |
| Depreciation | 0.57 | 0.70 | 0.04 | 0.71 | 1.11 | 0.51 | 0.71 | 0.38 |
| Interest | 1.32 | 0.49 | 0.38 | 0.54 | 0.74 | 0.33 | 0.46 | 0.35 |
| Profit before tax | 8.79 | 6.56 | 7.96 | 5.92 | 11.10 | 4.63 | 6.02 | 3.95 |
| Tax | 2.21 | 1.54 | 2.29 | 1.91 | 2.69 | 1.15 | 1.66 | 0.92 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 102 | 67.80 | 44.65 | 31.69 | 21.77 | 9.62 | 4.93 |
| Revenue growth | +50.3% | +51.9% | +40.9% | +45.6% | +126.3% | +95.1% | - |
| Other income | 4.17 | 3.14 | 2.20 | 1.15 | 0.60 | 0.16 | 0.07 |
| Total expenses | 77.57 | 50.14 | 35.78 | 25.43 | 19.06 | 8.36 | 5.21 |
| Employee cost | 0.00 | 2.51 | 1.55 | 1.39 | 1.10 | 0.70 | 0.71 |
| EBITDA | 24.33 | 17.66 | 8.87 | 6.26 | 2.71 | 1.26 | (0.28) |
| EBITDA margin | +23.9% | +26.1% | +19.9% | +19.8% | +12.5% | +13.1% | -5.7% |
| Depreciation | 1.86 | 1.53 | 0.77 | 0.36 | 0.20 | 0.14 | 0.12 |
| Interest | 1.66 | 1.38 | 0.51 | 0.48 | 0.13 | 0.41 | 0.76 |
| Profit before tax | 24.98 | 17.89 | 9.79 | 6.57 | 2.98 | 0.87 | (1.09) |
| Tax | 6.89 | 4.85 | 2.75 | 0.56 | (0.96) | 0.22 | (0.28) |
| Net profit | 18.09 | 13.04 | 7.03 | 6.01 | 3.94 | 0.65 | (0.82) |
| Net profit margin | +17.8% | +19.2% | +15.7% | +19.0% | +18.1% | +6.8% | -16.6% |
| EPS (βΉ) | 15.50 | 11.35 | 6.13 | 5.23 | 4.93 | 1.26 | (2.57) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.93 | 11.50 | 11.50 | 11.50 | 8.00 | 5.00 | 3.10 |
| Reserves & surplus | 83.43 | 54.23 | 41.18 | 34.13 | (3.22) | (5.47) | (6.10) |
| Shareholders' funds (net worth) | 99.09 | 65.73 | 52.68 | 45.63 | 4.78 | (0.47) | (3.00) |
| Secured loans | 21.20 | 13.02 | 6.20 | 2.73 | 0.60 | 0.00 | 0.00 |
| Unsecured loans | 3.40 | 1.87 | 0.00 | 0.65 | 1.86 | 4.53 | 6.46 |
| Total debt | 24.60 | 14.89 | 6.20 | 3.38 | 2.46 | 4.53 | 6.46 |
| Total liabilities | 124 | 80.69 | 58.94 | 49.08 | 7.30 | 4.11 | 3.52 |
| Assets | |||||||
| Gross block | 33.91 | 18.26 | 9.55 | 4.27 | 2.23 | 1.77 | 1.22 |
| Net block | 28.59 | 14.80 | 7.62 | 3.11 | 1.43 | 1.18 | 0.77 |
| Capital work in progress | 0.00 | 0.54 | 4.03 | 0.23 | 0.00 | 0.00 | 0.00 |
| Investments | 19.74 | 12.49 | 4.40 | 4.04 | 0.05 | 0.00 | 0.00 |
| Inventories | 23.22 | 16.57 | 11.06 | 7.17 | 3.71 | 5.27 | 0.94 |
| Sundry debtors | 49.34 | 20.40 | 13.76 | 12.15 | 4.97 | 0.64 | 1.31 |
| Cash & bank balances | 4.07 | 2.11 | 6.01 | 13.77 | 0.13 | 0.09 | 0.12 |
| Loans & advances | 33.41 | 30.05 | 22.15 | 14.77 | 1.83 | 1.74 | 0.45 |
| Total current assets | 110 | 69.13 | 52.98 | 47.86 | 10.64 | 7.74 | 2.82 |
| Total current liabilities | 34.50 | 16.64 | 14.29 | 7.42 | 6.53 | 7.34 | 2.87 |
| Net working capital | 75.54 | 52.49 | 38.69 | 40.44 | 4.11 | 0.40 | (0.05) |
| Total assets | 124 | 80.69 | 58.94 | 49.08 | 7.30 | 4.11 | 3.52 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.11 | 6.01 | 13.77 | 0.13 | 0.01 | 0.12 | 0.04 |
| Net cash from operating activities | 7.93 | 1.97 | 0.90 | (16.60) | (0.19) | 1.48 | (0.59) |
| Net cash from investing activities | (20.07) | (7.88) | (11.01) | (5.56) | (0.50) | (0.56) | (0.08) |
| Net cash from financing activities | 14.10 | 2.01 | 2.35 | 35.80 | 0.80 | (0.96) | 0.76 |
| Net change in cash | 1.96 | (3.90) | (7.76) | 13.64 | 0.11 | (0.03) | 0.08 |
| Closing cash | 4.07 | 2.11 | 6.01 | 13.77 | 0.13 | 0.09 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +50.3% | +51.9% | +40.9% | +45.6% | +126.3% | +95.1% | - |
| EBITDA growth | +37.8% | +99.1% | +41.7% | +131.0% | +115.1% | +550.0% | - |
| PBT growth | +39.6% | +82.7% | +49.0% | +120.5% | +242.5% | +9998.0% | +9997.0% |
| Net income growth | +38.7% | +85.5% | +17.0% | +52.5% | +506.2% | +179.3% | - |
| Revenue CAGR (3Y) | +47.6% | +46.0% | +66.8% | +85.9% | - | - | - |
| EBITDA CAGR (3Y) | +57.3% | +86.8% | +91.7% | - | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +17.8% | +19.2% | +15.8% | +19.0% | +18.1% | +6.8% | -16.4% |
| Return on capital employed | +26.1% | +27.6% | +19.1% | +23.7% | +31.0% | +19.2% | 0.0% |
| Return on net worth | +22.0% | +22.0% | +14.3% | +22.4% | +60.8% | +63.0% | 0.0% |
| Debt / equity | 0.24 | 0.18 | 0.10 | 0.12 | 1.62 | 0.00 | 0.00 |
| Long-term debt / equity | 0.08 | 0.08 | 0.04 | 0.04 | 1.36 | 0.00 | 0.00 |
| Interest cover | 7.47 | 8.56 | 6.30 | 8.14 | 5.18 | 36.61 | -190.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 3.91 | 4.88 | 6.46 | 9.75 | 10.89 | 6.43 | 4.04 |
| Inventory turnover | 5.12 | 4.91 | 4.90 | 5.83 | 4.85 | 3.10 | 5.24 |
| Debtors turnover | 2.92 | 3.97 | 3.45 | 3.70 | 7.76 | 9.87 | 3.76 |
| EPS (βΉ) | 15.16 | 11.35 | 6.13 | 5.23 | 4.93 | 1.26 | (2.57) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 79.91 | 57.16 | 45.81 | 39.68 | 5.97 | (0.94) | (9.69) |
Investments & Acquisitions by Trident Lifeline
Trident Lifeline has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tll Herbal.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Anti-freeze preparations and chemical-related products are manufactured by Tll Herbal. | tllherbal.com | Surat, India | 2019 | Jul 2023 | $572,613 |
Complete acquisition details for Trident Lifeline
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Trident Lifeline
3 dated milestones of Trident Lifeline across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Trident Lifeline is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Tll Herbal.
Web traffic of Trident Lifeline
The website of Trident Lifeline (tridentlifeline.com) receives about 1K visits a month.
- Monthly visits1K
▼ 4% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Trident Lifeline (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Trident Lifeline
Complete news archive for Trident Lifeline
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Trident Lifeline
Trident Lifeline was founded in 2014.
Trident Lifeline is headquartered in Surat, India. It is registered at Surat, Gujarat, India.
Trident Lifeline has 74 employees.
The primary company behind Trident Lifeline, Trident Lifeline Limited, reported revenue of βΉ138 Cr for FY 2026, up 48% year on year.
Trident Lifeline was established in 2014 in Surat, India, within the pharmaceutical sector. Operations focus on the production of liquid orals, topical preparations, capsules, and additional drug formulations. Manufacturing activities are centered in India, supporting domestic pharmaceutical needs. Leadership is provided by Managing Director Hardik Desai, with the company maintaining a domain at tridentlifeline.com for operational purposes.
Trident Lifeline offers Pharmaceuticals and Nutraceuticals.
Yes, Trident Lifeline is publicly traded on BSE under the ticker symbol TLL.
Trident Lifeline has made 1 acquisition, including Tll Herbal.
Trident Lifeline operates through Trident Lifeline Limited.
The legal entities of Trident Lifeline currently have 9 directors, including Hardik Jigishkumar Desai, Shravan H Patel, Nikita Sharma and others.
